comparemela.com

Latest Breaking News On - Axcella health - Page 19 : comparemela.com

DelveInsight Business Research, LLP: Overt Hepatic Encephalopathy Market is Booming Worldwide The market size is supposed to increase at a decent compound annual growth rate (CAGR) during the Study Period [2019-2032], Evaluates DelveInsight

Investegate |NOVARTIS AG CHF0 50(REGD) Announcements | NOVARTIS AG CHF0 50(REGD): Novartis announces new organizational structure to accelerate growth, strengthen pipeline and increase productivity

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis announces new organizational structure to accelerate growth, strengthen pipeline and increase productivity

SVB Leerink Comments on Axcella Health Inc s Q1 2022 Earnings (NASDAQ:AXLA)

Axcella Health Inc. (NASDAQ:AXLA – Get Rating) – Equities research analysts at SVB Leerink issued their Q1 2022 earnings estimates for Axcella Health in a research report issued on Wednesday, March 30th. SVB Leerink analyst T. Smith anticipates that the company will post earnings of ($0.42) per share for the quarter. SVB Leerink currently has […]

Long COVID is the newest target of vaccine and drug developers (NASDAQ:MRNA)

Major drug companies, including leading COVID-19 vaccine developers, have joined efforts to discover a potential treatment for long COVID, a condition affecting over 100 million.

William Hinshaw Purchases 13,089 Shares of Axcella Health Inc (NASDAQ:AXLA) Stock

Axcella Health Inc. (NASDAQ:AXLA – Get Rating) CEO William Hinshaw purchased 13,089 shares of Axcella Health stock in a transaction dated Wednesday, March 16th. The stock was bought at an average price of $1.91 per share, with a total value of $24,999.99. The acquisition was disclosed in a document filed with the Securities & Exchange […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.